What Does Tysabri PML Monitoring Involve?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concern

If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). The legacy of medical research provides a framework for understanding how regular monitoring can detect early signs of JC virus reactivation. This page explains the evidence-based monitoring protocols and what they can and cannot reveal about PML risk.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and no specific treatment exists to halt its progression once established. Clinical presentation of PML often includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on brain imaging, typically magnetic resonance imaging showing characteristic white matter lesions, and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The latency between Tysabri exposure and PML onset can vary widely, from months to several years, complicating the attribution of harm to the drug. The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte trafficking into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected therapeutic benefit when initiating or continuing therapy.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The prescribing information includes a boxed warning that explicitly states Tysabri increases PML risk and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to ensure patients are informed of risks and monitored for symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the magnitude of risk, particularly for patients who developed PML after shorter treatment durations or without recognized risk factors. For patients who develop PML after Tysabri use, attorney-related considerations include the statute of limitations for filing a claim in New Jersey. The statute of limitations for personal injury actions in New Jersey is generally two years from the date the injury was discovered or reasonably should have been discovered. In the context of Tysabri-associated PML, the discovery date may be when the patient received a confirmed diagnosis, not necessarily when symptoms first appeared. Given the variable latency between exposure and documented harm, careful documentation of the timeline is essential. The timeline includes the start of Tysabri therapy, duration of treatment, onset of neurological symptoms, date of PML diagnosis, and any prior immunosuppressant use. These factors can influence both the legal viability of a claim and the assessment of whether the manufacturer's warnings were adequate.

Risk Mitigation and Monitoring

Patients and their families should be aware that the TOUCH program requires regular monitoring, but PML can still occur despite compliance. The prescribing information advises healthcare professionals to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis or failure to act on early symptoms may affect patient outcomes and legal considerations. In summary, the medical evidence establishes a clear causal link between Tysabri and PML, with recognized risk factors and a mandated risk mitigation program. For patients harmed by PML, the statute of limitations in New Jersey requires prompt legal evaluation after diagnosis. The adequacy of warnings and the timeline between exposure and harm are critical elements in any potential claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New Jersey?

In New Jersey, the statute of limitations for personal injury actions is generally two years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-associated PML, the discovery date is typically when the patient receives a confirmed PML diagnosis, not when symptoms first appear. It is crucial to consult an attorney promptly after diagnosis to ensure the claim is filed within the statutory period.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when assessing the risk-benefit profile of continuing therapy.

What is the TOUCH Prescribing Program?

The TOUCH Prescribing Program is a restricted distribution system mandated by the FDA for Tysabri. It is designed to ensure that patients are informed of the risks of PML and are monitored regularly for symptoms. Enrollment in the program is required for all patients prescribed Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.